

Given the significance of cough as a clinical problem worldwide and the paucity of safe and effective antitussive drugs, high-quality investigation in the field of cough remains a priority. The optimal clinical study should include both subjective and objective cough-specific end points, measured in appropriately selected subject populations. The availability of practical, well-validated automated cough monitors will represent a major breakthrough in clinical cough research and is awaited with great anticipation.

Competing interests: None.

Thorax 2009;**64**:372–373. doi:10.1136/thx.2008.111021

REFERENCES

1. **Burt CW**, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999–2000. *Vital Health Stat* 2004;**13**:1–70.
2. **Morice AH**, Fontana GA, Sovijarvi AR, *et al.* The diagnosis and management of chronic cough. *Eur Respir J* 2004;**24**:481–92.
3. **Kardos P**, Cegla U, Gillissen A, *et al.* The German Respiratory Society's guideline for the diagnosis and treatment of patients with acute and chronic cough (German). *Med Klin (Munich)* 2004;**99**:468–75.
4. **Irwin RS**, Baumann MH, Bolser DC, *et al.* Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. *Chest* 2006;**129**(Suppl):1–23S.
5. **Morice AH**, McGarvey L, Pavord I, *et al.* British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. *Thorax* 2006;**61**(Suppl 1):i1–24.
6. **Kohno S**, Ishida T, Uchida Y, *et al.* The Japanese Respiratory Society guidelines for management of cough. *Respirology* 2006;**11**(Suppl 4):S135–86.
7. **Morice AH**, Fontana GA, Belvisi MG, *et al.* European Respiratory Society guidelines on the assessment of cough. *Eur Respir J* 2007;**29**:1256–76.
8. **McLeod RL**, Correll CC, Jia Y, *et al.* TRPV1 antagonists as potential antitussive agents. *Lung* 2008;**186**(Suppl 1):S59–65.
9. **McLeod RL**, Bolser DC, Jia Y, *et al.* Antitussive effect of nociceptin/orphanin FQ in experimental cough models. *Pulm Pharmacol Ther* 2002;**15**:213–6.
10. **Belvisi MG**. Preclinical assessment of novel therapeutics on the cough reflex: cannabinoid agonists as potential antitussives. *Lung* 2008;**186**(Suppl 1):S66–9.
11. **Dicpinigaitis PV**. Experimentally induced cough. *Pulm Pharmacol Ther* 2007;**20**:319–24.
12. **Birring SS**, Prudon B, Carr AJ, *et al.* Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax* 2003;**58**:339–43.
13. **French CT**, Irwin RS, Fletcher KE, *et al.* Evaluation of a cough-specific quality-of-life questionnaire. *Chest* 2002;**121**:1123–31.
14. **Eccles R**. The powerful placebo in cough studies? *Pulm Pharmacol Ther* 2002;**15**:303–8.
15. **Decalmer SC**, Webster D, Kelsall AA, *et al.* Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring? *Thorax* 2007;**62**:329–34.
16. **Smith J**, Woodcock A. New developments in the objective assessment of cough. *Lung* 2008;**186**(Suppl 1):S48–54.
17. **Kelsall A**, Decalmer S, McGuinness K, *et al.* Sex differences and predictors of objective cough frequency in chronic cough. *Thorax* 2009;**64**:391–6.
18. **Fujimura M**, Kasahara K, Kamio Y, *et al.* Female gender as a determinant of cough threshold to inhaled capsaicin. *Eur Respir J* 1996;**9**:1624–6.
19. **Dicpinigaitis PV**, Rauf K. The influence of gender on cough reflex sensitivity. *Chest* 1998;**113**:1319–21.
20. **Kastelik JA**, Thompson RH, Aziz I, *et al.* Sex-related differences in cough reflex sensitivity in patients with chronic cough. *Am J Respir Crit Care Med* 2002;**166**:961–4.
21. **French CT**, Fletcher KE, Irwin RS. Gender differences in health-related quality of life in patients complaining of chronic cough. *Chest* 2004;**125**:482–8.
22. **French CT**, Fletcher KE, Irwin RS. A comparison of gender differences in health-related quality of life in acute and chronic coughers. *Chest* 2005;**127**:1991–8.
23. **Sekizawa K**, Ujiie Y, Itabashi S, *et al.* Lack of cough reflex in aspiration pneumonia. *Lancet* 1990;**335**:1228–9.
24. **Nakazawa H**, Sekizawa K, Ujiie Y, *et al.* Risk of aspiration pneumonia in the elderly (letter). *Chest* 1993;**103**:1636–7.
25. **Katsumata U**, Sekizawa K, Ebihara T, *et al.* Aging effects on cough reflex (letter). *Chest* 1995;**107**:290–1.

Lung alert

Pseudomonas: is chronic infection behind acute exacerbations in COPD?

Approximately half of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with bacterial infection, and *Pseudomonas aeruginosa* is increasingly recognised as an important pathogen. Up to 13% of AECOPD are associated with *P aeruginosa* in patients with severe airflow obstruction. Whether chronic infection with *P aeruginosa* predisposes to AECOPD is not entirely clear.

Sputum samples positive for *P aeruginosa* taken from 13 patients with AECOPD were compared with blood samples from 10 patients with acute bacteraemia. Eight of the patients with COPD had sequential positive samples of *P aeruginosa* at other AECOPD. Samples were molecularly typed and production of virulence factors, mutation rates and motility were investigated.

Each of the eight patients with COPD with sequential infections had established *P aeruginosa* clones. There was no indication of transmission of these clones between patients. These strains showed aspects of the characteristic evolution of chronic *P aeruginosa* infections seen in patients with cystic fibrosis (CF). Unsurprisingly, recurrent infections were linked with bacteria which were hypermutable and displayed increasing antibiotic resistance. When compared with the *P aeruginosa* isolates from blood, those from the lung produced more biofilm and were less cytotoxic and motile.

The authors have shown that expression of virulence factors differs in acute and chronic *P aeruginosa* infection. This study therefore supports others in demonstrating that *P aeruginosa* can cause a chronic infection in COPD similar to that seen in patients with CF. Using data from CF studies may provide important information on the management of this process.

- ▶ Marti'nez-Solano L, Macia MD, Fajardo A, *et al.* Chronic *Pseudomonas aeruginosa* infection in chronic obstructive pulmonary disease. *Chronic Infect Dis* 2008;**47**:1526–33.

K Lindsay

Correspondence to: Ms K Lindsay, Medical Student, University College London, London, UK; k.lindsay@ucl.ac.uk